Treatment for Patients With Newly Diagnosed Glioblastoma

• Autores: Marc C. Chamberlain, Roger Stupp, Steven A. Toms, Santosh Kesari
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 21, 2016, págs. 2348-2349
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen
  • español

    Tumor-treating fields are a novel approach to the treatment of cancer. In vitro and animal studies have demonstrated that the use of alternating electrical fields, at a frequency specifically tuned to penetrate tumor cells, interferes with microtubule formation, proper localization of the cytokinetic contractile ring, and chromosomal segregation, leading to cell cycle arrest, apoptosis, and reduced clonogenic potential.1- 3 Little progress has been made in the treatment of glioblastoma over the last decade, yet our study demonstrated a significant improvement in both progression-free and overall survival in patients with glioblastoma.

  • English

    Dr Stupp and colleagues1 reported on the combined use of temozolomide and tumor-treating fields (TTFields) compared with temozolomide alone as adjuvant therapy in patients with newly diagnosed glioblastoma. The study of 315 patients demonstrated improvement in progression-free survival (3.1 months) and overall survival (4.9 months) in the TTFields-treated cohort (210 patients). The question is whether this study, an interim analysis of the total study population of 695 patients, is sufficiently compelling to change current therapies for glioblastoma.